A phloroglucinol dual-release preparation and preparation method thereof
By combining the fast-release and sustained release parts in the phlogenetol double-release preparation, using specific materials and proportions to optimize the dissolution curve, the problem of the unsustainable therapeutic effect of existing phlogenetol oral collapse tablets is solved, and rapid The onset and 24-hour constant treatment effect improve the patient's medication compliance and safety.
Patent Information
- Application Number
- CN202410081094.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-19
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-01-19
AI Technical Summary
After the current phthalglucopherol oral collapse tablets take effect quickly, the blood drug concentration peaks, resulting in patients requiring frequent medication to control pain, increasing the risk of adverse reactions, and the treatment effect is not sustainable.
The phlogenetic double-release preparation is used to combine the instant-release part and the sustained-release part. The instant-release part contains 10% to 40% phlogenetic, and the sustained-release part contains 10% to 40% phlogenetic. Using cross-linked povidone and dry starch as disintegrants, hydroxypropyl cellulose and polyoxyethylene as sustained release agents, the dissolution curve is optimized to achieve rapid onset and a constant therapeutic effect of 24 hours.
The phlogenesol has been achieved to quickly reach the blood drug concentration required for treatment, and provides a continuous and stable blood drug concentration, which improves the patient's medication compliance, reduces the risk of adverse reactions caused by frequent medication, and provides a rapid and continuous 24 Pain relief effect for hours.
Smart Images

Figure CN118045072B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of pharmaceutical preparations, and in particular to a phloroglucinol dual-release preparation and a preparation method thereof. Background Art
[0002] (1) Pharmacological characteristics of phloroglucinol: Phloroglucinol is a myotropic, non-atropine, non-opioid pure smooth muscle antispasmodic drug. It can directly act on the smooth muscles of the urogenital and gastrointestinal tracts, and is clinically used to treat acute gynecological spasmodic pain; spastic urethral, bladder, and renal colic; acute spasmodic pain caused by digestive and biliary dysfunction; and adjuvant treatment of uterine contractions during pregnancy. Compared with other smooth muscle antispasmodics, phloroglucinol has the characteristic of not having an anticholinergic effect. While relieving smooth muscle spasms, it will not produce a series of anticholinergic adverse reactions, nor will it cause symptoms such as hypotension, increased heart rate, and arrhythmia, and has minimal effect on cardiovascular function. It only acts on spasmodic smooth muscles and has little effect on normal smooth muscles. Regarding the effect on the physiological contraction of smooth muscle, phloroglucinol has no effect on the physiological contraction of the gastrointestinal tract, bile duct, biliary sphincter, urethra and uterus at a dose sufficient to produce an antispasmodic effect; regarding the effect on bile secretion, low doses of phloroglucinol will not change the amount and composition of bile secretion, while at higher doses, it can increase bile secretion but will not change its composition; regarding the effect on the cardiovascular system, phloroglucinol will not change the blood pressure, heart rate and cardiac blood supply of animals.
[0003] (2) Pharmacokinetic characteristics of phloroglucinol: After oral administration of phloroglucinol, the plasma reaches a peak between 15 and 20 minutes. The tissue distribution of phloroglucinol is rapid and significant. The liver metabolizes it by glucuronic acid conjugation. It is excreted in the urine in the form of glucuronic acid conjugation and in the bile in the form of free and conjugated forms. The half-life is about 15 minutes. The blood concentration decreases rapidly within 4 hours after administration and then decreases slowly.
[0004] (3) Clinical application of phloroglucinol: Phloroglucinol is a smooth muscle antispasmodic drug, mainly used to treat acute spasmodic pain caused by digestive system and biliary dysfunction; acute spasmodic urethral, bladder, and renal colic; gynecological spasmodic pain; and adjuvant treatment of uterine contractions during pregnancy. It has seven major applications in the field of gynecology and obstetrics.
[0005] As a myotropic, non-atropine, non-opioid pure smooth muscle spasmolytic drug, phloroglucinol does not interfere with the physiological contraction rhythm and amplitude of normal smooth muscle, does not produce anticholinergic adverse reactions, has the characteristics of rapid onset, obvious effect, and good patient tolerance. It has a good analgesic effect and is currently widely used in clinical practice.
[0006] Phloroglucinol oral preparation was approved for marketing in France by TEVA SANTE in December 2005. The dosage form is: orodisintegrating tablets (phloroglucinol orodisintegrating tablets). This product can disintegrate and take effect within 1 minute after oral administration, and the blood drug concentration reaches the peak between 15 and 20 minutes. The half-life is about 15 minutes. Therefore, patients need to take it several times within 24 hours to effectively control pain, which brings inconvenience to patients and increases the risk of adverse drug reactions.
[0007] In order to overcome the shortcomings of existing phloroglucinol orally disintegrating tablets, increase patient compliance, reduce the risk of adverse reactions caused by multiple administrations, and provide patients with pain with a rapid and one-day pain relief product, the present invention provides a phloroglucinol dual-release preparation and a preparation method thereof to solve the above problems. Summary of the invention
[0008] In view of this, the present invention proposes a phloroglucinol dual-release preparation and a preparation method thereof, which can achieve a constant 24-hour therapeutic effect while taking effect quickly.
[0009] The technical solution of the present invention is achieved in this way:
[0010] A phloroglucinol dual-release preparation comprises a rapid-release portion and a sustained-release portion, wherein the mass ratio of the rapid-release portion to the sustained-release portion is 26-40:74-60; the rapid-release portion comprises the following raw materials and auxiliary materials: phloroglucinol and a disintegrant, wherein the weight percentage of phloroglucinol in the rapid-release portion is 10%-40%; the sustained-release portion comprises the following raw materials and auxiliary materials: phloroglucinol and a sustained-release agent, wherein the weight percentage of phloroglucinol in the sustained-release portion is 10%-40%; the disintegrant comprises cross-linked polyvinylpyrrolidone and dry starch in a mass ratio of 1:0.4-0.6, wherein the particle size of the cross-linked polyvinylpyrrolidone is 40-150 μm; the sustained-release agent comprises hydroxypropyl cellulose and polyoxyethylene in a mass ratio of 1:1.5-2.5, wherein the molecular weight of the hydroxypropyl cellulose is 50,000-1,250,000.
[0011] Furthermore, the preparation is a tablet, and the rapid-release portion is made of the following raw materials and auxiliary materials: phloroglucinol, filler, disintegrant, glidant, and lubricant; the sustained-release portion is made of the following raw materials and auxiliary materials: phloroglucinol, filler, sustained-release agent, binder, glidant, and lubricant.
[0012] Furthermore, the preparation is a capsule, the rapid-release part is made of the following raw materials and auxiliary materials: phloroglucinol, a filler, a disintegrant, and a binder; the sustained-release part is made of the following raw materials and auxiliary materials: phloroglucinol, a filler, a sustained-release agent, and a binder.
[0013] Furthermore, the preparation also contains a filler, which is at least one of microcrystalline cellulose and directly compressed lactose; the particle size of the microcrystalline cellulose is 80 to 150 μm, and the particle size of the directly compressed lactose is 50 to 200 μm.
[0014] Furthermore, the adhesive is at least one of povidone K30 and povidone K90; the glidant is at least one of silicon dioxide and talc; and the lubricant is at least one of magnesium stearate, calcium stearate, polyethylene glycol, and light castor oil.
[0015] Furthermore, the preparation is a tablet, and the immediate-release portion is made of the following raw materials and auxiliary materials in parts by weight: 30-40 parts of phloroglucinol, 48-62 parts of filler, 6-8 parts of disintegrant, 1.5-2.5 parts of glidant, and 0.8-1.2 parts of lubricant; the sustained-release portion is made of the following raw materials and auxiliary materials in parts by weight: 35-45 parts of phloroglucinol, 30-40 parts of filler, 15-25 parts of sustained-release agent, 4-6 parts of binder, 0.4-0.6 parts of glidant, and 0.8-1.2 parts of lubricant.
[0016] Furthermore, the preparation is a capsule, and the immediate-release portion is made of the following raw and auxiliary materials in parts by weight: 30-40 parts of phloroglucinol, 40-60 parts of a filler, 6-8 parts of a disintegrant, and 5-7 parts of a binder; the sustained-release portion is made of the following raw and auxiliary materials in parts by weight: 35-45 parts of phloroglucinol, 20-30 parts of a filler, 20-30 parts of a sustained-release agent, and 7-10 parts of a binder.
[0017] Furthermore, the preparation is a tablet, and the preparation method of the immediate release part of the tablet comprises the following steps: according to the weight ratio of the raw materials and auxiliary materials of the immediate release part, phloroglucinol, filler, disintegrant, and glidant are taken, mixed for 15-25 minutes, and then a lubricant is added and mixed for 10-20 minutes.
[0018] Further, the sustained-release portion of the tablet is prepared by method A or method B;
[0019] Method A comprises the following steps:
[0020] S1. Mixing and preparing materials: according to the weight ratio of the raw materials and auxiliary materials of the sustained-release part, take phloroglucinol, filler, sustained-release agent, and binder, add them into a wet mixer and mix for 8-12 minutes, and add 25-35% v / v ethanol solution thereto, stir and granulate, and granulate with a 18-22 mesh screen;
[0021] S2. Drying: Dry in a circulating oven at 60-80°C for 60-120 min; use a fluidizing dryer at 100-120°C inlet and 60-80°C outlet for 20-50 min;
[0022] S3, granulation: granulation is performed using a sieve, and D50 after granulation is 450-550 μm;
[0023] S4, total mixing: put the granulated granules into the total mixer, add the flow aid and lubricant to mix;
[0024] S5, tableting: add the mixed phloroglucinol immediate-release intermediate into the 1# hopper of the double-layer tablet press, add the sustained-release intermediate into the 2# hopper of the double-layer tablet press, and compress the mixture into tablets;
[0025] Method B comprises the following steps:
[0026] S1. Mixing materials: according to the weight ratio of the raw and auxiliary materials of the sustained-release part, take phloroglucinol, filler, sustained-release agent and adhesive and mix them evenly;
[0027] S2. Material preparation: Granulate with a dry granulator, and perform granulation on the granules after granulation, and the D50 after granulation is 450-550 μm;
[0028] S3, total mixing: put the granulated granules into the total mixer, add the flow aid and lubricant for mixing;
[0029] S4, tableting, adding the mixed phloroglucinol quick-release intermediate into the 1# hopper of the double-layer tablet press, adding the sustained-release intermediate into the 2# hopper of the double-layer tablet press, and tableting is performed.
[0030] Furthermore, the preparation method of the capsule comprises the following steps:
[0031] (1) Immediate release
[0032] S1. According to the weight ratio of the raw materials and auxiliary materials of the immediate release part, phloroglucinol, filler, disintegrant, and 45-55%wt of the binder are mixed evenly and set aside;
[0033] S2. Use the remaining adhesive to add 25-35% v / v ethanol solution to prepare a wetting solution for later use.
[0034] S3, adding a binder to the mixed material in S1 to prepare a wetting liquid to prepare a soft material, and extruding, spheronizing and drying the soft material to obtain quick-release pellets;
[0035] (2) Sustained-release part: according to the weight ratio of the raw materials and auxiliary materials of the sustained-release part, phloroglucinol, filler, sustained-release agent and binder are mixed evenly, and a soft material is prepared with 25-35% v / v ethanol solution; the soft material is extruded, spheronized and dried to obtain quick-release pellets;
[0036] (3) Filling capsules: Put the quick-release pellets and sustained-release pellets into capsules.
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] (1) The present invention is based on the pharmacological and pharmacokinetic characteristics of phloroglucinol, and combined with the defects of existing phloroglucinol orally disintegrating tablets, in order to increase the compliance of patients with medication, so that the drug can both quickly take effect and continuously and stably exert its therapeutic effect. The phloroglucinol dual-release preparation provided by the present invention can not only allow phloroglucinol to quickly reach the blood drug concentration required for treatment, but also continuously provide a steady-state blood drug concentration, thereby achieving a rapid onset and a constant 24-hour therapeutic effect.
[0039] (2) The present invention combines a certain ratio of the immediate-release portion and the sustained-release portion, uses a certain ratio and a specific particle size of cross-linked polyvinylpyrrolidone and dry starch as disintegrants, and uses a certain ratio and a specific molecular weight of hydroxypropyl cellulose and polyoxyethylene as sustained-release agents to optimize the dissolution curve and effectively improve the stability of the preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 Dissolution curve of phloroglucinol dual-release tablets according to Example 1 of the present invention.
[0041] Figure 2 Dissolution curve of phloroglucinol dual-release capsules in Example 3 of the present invention.
[0042] Figure 3 Dissolution curve of phloroglucinol orally disintegrating tablets.
[0043] Figure 4 , Example 1: Related substance spectrum of phloroglucinol double-release tablets at month 0.
[0044] Figure 5 Dissolution curves of phloroglucinol dual-release tablets in accelerated tests at 0, 1, 2, 3 and 6 months.
[0045] Figure 6 , Example 3: Spectrum of related substances of phloroglucinol double-release capsules at month 0.
[0046] Figure 7 Dissolution curves of phloroglucinol double-release capsules in accelerated tests at 0, 1, 2, 3 and 6 months. DETAILED DESCRIPTION
[0047] In order to better understand the technical content of the present invention, specific embodiments are provided below to further illustrate the present invention.
[0048] Unless otherwise specified, the experimental methods used in the embodiments of the present invention are all conventional methods.
[0049] Unless otherwise specified, the materials, reagents, etc. used in the embodiments of the present invention can be obtained from commercial sources.
[0050] Example 1 - Phloroglucinol dual-release tablets
[0051] (I) Prescription
[0052] The phloroglucinol double-release tablets have a quick-release portion accounting for 35.5% of the total content of the phloroglucinol double-release tablets, and a sustained-release portion accounting for 64.5% of the total content of the phloroglucinol double-release tablets.
[0053] Table 1 Prescription of Phloroglucinol Double Release Tablets (by weight percentage)
[0054]
[0055] The above disintegrant is composed of cross-linked polyvinylpyrrolidone and dry starch in a mass ratio of 1:0.5;
[0056] The sustained-release agent is composed of hydroxypropyl cellulose and polyoxyethylene in a mass ratio of 1:2.0, and the molecular weight of hydroxypropyl cellulose is about 100,000.
[0057] The particle size of the cross-linked polyvinylpyrrolidone is 100 μm, the particle size of the microcrystalline cellulose is 100 μm, and the particle size of the directly compressed lactose is 100 μm.
[0058] (II) Preparation steps
[0059] 1. Immediate release part: Mix phloroglucinol, filler, disintegrant and glidant for 20 minutes, then add lubricant and mix for 15 minutes for later use.
[0060] 2. Sustained release part:
[0061] ① Mixing and preparing materials: Take the phloroglucinol, filler, sustained-release agent and binder of the sustained-release part and add them into a wet mixer and mix for 10 minutes, and then add an appropriate amount of 30 v / v% ethanol solution and stir to granulate. Use a 20-mesh screen to granulate.
[0062] ② Drying: Use a circulating oven to dry at 60℃~80℃; use a boiling dryer with an inlet of 100℃~120℃ and an outlet of 60℃~80℃ for drying.
[0063] ③ Granulation: Use a 20-mesh sieve to granulate, the particle size is D50=700μm.
[0064] ④ Total mixing: Place the granules in a total mixer, add flow aids and lubricants for mixing.
[0065] ⑤ Tableting: Add the mixed phloroglucinol quick-release intermediate into the 1# hopper of the double-layer tablet press, and add the sustained-release intermediate into the 2# hopper of the double-layer tablet press, and then tablets are obtained.
[0066] Example 2 - Phloroglucinol dual-release tablets
[0067] The difference from Example 1 is that the preparation method of the sustained-release part is different:
[0068] Preparation of sustained-release part:
[0069] ① Mixing materials: Take the phloroglucinol in the sustained-release part, filler, sustained-release agent and adhesive and mix them evenly.
[0070] ②Material preparation: Granulate with a dry granulator and resize the granules. D50 after resize = 500 μm
[0071] ③ Total mixing: Place the granulated particles in a total mixer, add flow aids and lubricants for mixing.
[0072] ④ Tableting: Add the mixed phloroglucinol quick-release intermediate into the 1# hopper of the double-layer tablet press, add the sustained-release intermediate into the 2# hopper of the double-layer tablet press, and press into tablets.
[0073] Example 3 - Phloroglucinol Double Capsules
[0074] (I) Prescription
[0075] The phloroglucinol double capsules have a quick-release portion that accounts for 35.5% of the total content of the phloroglucinol double capsules, and a sustained-release portion that accounts for 64.5% of the total content of the phloroglucinol double capsules.
[0076] Table 2 Prescription of Phloroglucinol Double Capsules (by weight percentage)
[0077]
[0078] The above disintegrant is composed of cross-linked polyvinylpyrrolidone and dry starch in a mass ratio of 1:0.5;
[0079] The sustained-release agent is composed of hydroxypropyl cellulose and polyoxyethylene in a mass ratio of 1:2.0, and the molecular weight of hydroxypropyl cellulose is about 100,000.
[0080] The particle size of the cross-linked polyvinylpyrrolidone is 100 μm, the particle size of the microcrystalline cellulose is 100 μm, and the particle size of the directly compressed lactose is 100 μm.
[0081] (II) Preparation method
[0082] 1. Immediate release
[0083] a Take the phloroglucinol in the immediate release portion, the filler, the disintegrant, and half of the prescribed amount of the binder and mix them evenly for later use.
[0084] B Use the remaining adhesive to prepare the wetting liquid for later use.
[0085] c. Add the mixed materials in item a to the adhesive to prepare the wetting liquid to prepare the soft material, and extrude, spheronize and dry the soft material to obtain the quick-release pellets.
[0086] 2. Sustained-release part: Take the phloroglucinol, filler, sustained-release agent and adhesive of the sustained-release part and mix them evenly, and use an appropriate amount of 30v / v% ethanol solution to prepare a soft material. The soft material is extruded, spheronized and dried to obtain quick-release pellets.
[0087] 3. Filling capsules: Put the quick-release pellets and sustained-release pellets into capsules.
[0088] Other embodiments,
[0089] The mass ratio of the immediate release part to the sustained release part is 26-40:74-60;
[0090] The mass ratio of cross-linked polyvinylpyrrolidone to dry starch in the disintegrant is 1:0.4-0.6;
[0091] The mass ratio of hydroxypropylcellulose to polyoxyethylene in the sustained-release preparation is 1:1.5-2.5;
[0092] The molecular weight of hydroxypropyl cellulose is 50,000 to 1,250,000;
[0093] Cross-linked polyvinylpyrrolidone particle size 40-150 μm;
[0094] The diameter of microcrystalline cellulose is 80-150μm, and the particle size of direct-compressed lactose is 50-200μm.
[0095] The purpose of the present invention can be achieved by adjusting within the above range.
[0096] 1. Dissolution Determination
[0097] The dissolution rates of the phloroglucinol dual-release preparations prepared in Examples 1 and 3 of the present invention were measured.
[0098] Dissolution medium: 0.1 mol / L hydrochloric acid solution.
[0099] Control: commercially available phloroglucinol orally disintegrating tablets.
[0100] The dissolution curve of phloroglucinol dual-release tablets in Example 1 of the present invention is as follows Figure 1 shown.
[0101] The dissolution curve of phloroglucinol dual-release capsules in Example 3 of the present invention is as follows Figure 2 shown.
[0102] Dissolution curve of phloroglucinol orally disintegrating tablets Figure 3 .
[0103] 2. Stability inspection
[0104] 1 Example 1 of the present invention Stability study of phloroglucinol dual-release tablets
[0105] Accelerated test conditions: Place the phloroglucinol double-release tablets at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 6 months, and take samples for testing at the 0th, 1st, 2nd, 3rd, and 6th month.
[0106] Chromatographic conditions: octadecylsilane bonded silica gel was used as filler, acetonitrile-water (40:60) (pH adjusted to 3.0 with glacial acetic acid) was used as mobile phase, detection wavelength was 265 nm, injection volume was 20 ul, and flow rate was 1.0 ml / min.
[0107] ① Related substance spectrum in October Figure 4 shown.
[0108] ②Content and related substances
[0109] Table 3 Example 1 Phloroglucinol dual-release tablets stability test content and related substances results
[0110]
[0111] ③Dissolution
[0112] Table 4 Dissolution results of stability study of phloroglucinol dual-release tablets in Example 1
[0113]
[0114] The dissolution curves of phloroglucinol dual-release tablets in the accelerated test in 0, 1, 2, 3, and 6 months are as follows Figure 5 shown.
[0115] 2 Study on the stability of phloroglucinol double-release capsules in Example 3 of the present invention
[0116] Accelerated test conditions: Place the phloroglucinol double-release capsules at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5% for 6 months, and take samples for testing at the 0th, 1st, 2nd, 3rd, and 6th month.
[0117] ① Related substance spectrum in October Figure 6 shown.
[0118] ②Content and stability data of related substances
[0119] Table 5 Results of stability study of phloroglucinol double-release capsules in Example 3 and related substances
[0120]
[0121] ③Dissolution stability data
[0122] Table 6 Dissolution results of stability study of phloroglucinol dual-release capsules in Example 3
[0123]
[0124]
[0125] The dissolution curves of phloroglucinol double-release capsules in the accelerated test in 0, 1, 2, 3 and 6 months are as follows Figure 7 shown.
[0126] In summary, the phloroglucinol double-release tablets prepared in Example 1 and the phloroglucinol double-release capsules prepared in Example 3 of the present invention have good stability.
[0127] Comparative Example 1
[0128] A phloroglucinol dual-release tablet, which is different from Example 1 in that the disintegrant of the immediate-release portion is cross-linked sodium carboxymethyl cellulose; and the sustained-release agent of the sustained-release portion is composed of ethyl cellulose and acrylic resin in a mass ratio of 1:1.
[0129] Dissolution and stability test results:
[0130] ①Content and related substances
[0131] Table 7 Comparative Example 1 Phloroglucinol Double Release Tablets Stability Test Content and Related Substances Results
[0132]
[0133] ②Dissolution
[0134] Table 8 Comparative Example 1 Phloroglucinol dual-release tablets stability study dissolution results
[0135]
[0136]
[0137] The results showed that the stability study and accelerated test lasted for 6 months. In the 6th month, the related substances of phloroglucinol double-release tablets were detected, and the maximum single impurity was ≥0.15%, and the total impurities were ≥0.21%.
[0138] Comparative Example 2
[0139] A phloroglucinol dual-release tablet, which is different from Example 1 in that the particle size of the cross-linked polyvinylpyrrolidone is 10 to 30 μm; and the sustained-release agent is composed of hydroxypropyl cellulose and polyoxyethylene in a mass ratio of 1:1.
[0140] ①Content and related substances
[0141] Table 9 Comparative Example 2 Phloroglucinol Double Release Tablets Stability Test Content and Related Substances Results
[0142]
[0143] ②Dissolution
[0144] Table 10 Comparative Example 2 Phloroglucinol Double Release Tablets Stability Study Dissolution
[0145]
[0146]
[0147] The results showed that the stability study and accelerated test lasted for 6 months. In the 6th month, the related substances of phloroglucinol double-release tablets were detected, and the maximum single impurity was ≥0.17%, and the total impurities were ≥0.23%.
[0148] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A phloroglucinol dual-release preparation, characterized in that: The invention is composed of a quick-release part and a sustained-release part, wherein the mass ratio of the quick-release part to the sustained-release part is 26-40:74-60; the preparation is a tablet or a capsule, The preparation is a tablet, and the quick-release part is made of the following raw materials and auxiliary materials in parts by weight: 30-40 parts of phloroglucinol, 48-62 parts of filler, 6-8 parts of disintegrant, 1.5-2.5 parts of glidant, and 0.8-1.2 parts of lubricant; the sustained-release part is made of the following raw materials and auxiliary materials in parts by weight: 35-45 parts of phloroglucinol, 30-40 parts of filler, 15-25 parts of sustained-release agent, 4-6 parts of binder, 0.4-0.6 parts of glidant, and 0.8-1.2 parts of lubricant; The preparation is a capsule, wherein the quick-release part is prepared from the following raw materials and auxiliary materials in parts by weight: 30-40 parts of phloroglucinol, 40-60 parts of a filler, 6-8 parts of a disintegrant, and 5-7 parts of a binder; the sustained-release part is prepared from the following raw materials and auxiliary materials in parts by weight: 35-45 parts of phloroglucinol, 20-30 parts of a filler, 20-30 parts of a sustained-release agent, and 7-10 parts of a binder; The disintegrant is composed of cross-linked polyvinylpyrrolidone and dry starch in a mass ratio of 1:0.4-0.6, and the particle size of the cross-linked polyvinylpyrrolidone is 40-150 μm; the sustained-release agent is composed of hydroxypropyl cellulose and polyoxyethylene in a mass ratio of 1:1.5-2.5, and the molecular weight of the hydroxypropyl cellulose is 50,000-1,250,000.
2. The phloroglucinol dual-release preparation according to claim 1, characterized in that: The filler is at least one of microcrystalline cellulose and directly compressed lactose; the particle size of the microcrystalline cellulose is 80 to 150 μm, and the particle size of the directly compressed lactose is 50 to 200 μm.
3. The phloroglucinol dual-release preparation according to claim 1, characterized in that: The adhesive is at least one of povidone K30 and povidone K90; the glidant is at least one of silicon dioxide and talc; the lubricant is at least one of magnesium stearate, calcium stearate, polyethylene glycol, and light castor oil.
4. The phloroglucinol dual-release preparation according to claim 1, characterized in that: The preparation is a tablet, and the preparation method of the immediate release part of the tablet comprises the following steps: according to the weight ratio of the raw materials and auxiliary materials of the immediate release part, phloroglucinol, filler, disintegrant and glidant are taken, mixed for 15-25 minutes, and then a lubricant is added and mixed for 10-20 minutes.
5. The phloroglucinol dual-release preparation according to claim 1, characterized in that: The sustained-release portion of the tablet is prepared by method A or method B; Method A comprises the following steps: S1. Mixing and preparing materials: according to the weight ratio of the raw materials and auxiliary materials of the sustained-release part, take phloroglucinol, filler, sustained-release agent, and binder, add them into a wet mixer and mix for 8-12 minutes, and add 25%-35% v / v ethanol solution thereto, stir and granulate, and granulate with a 18-22 mesh screen; S2. Drying: Use a circulating oven at 60-80℃ for drying for 60-120min; use a boiling dryer at 100-120℃ inlet and 60-80℃ outlet for drying for 20-50min; S3, granulation: granulation is performed using a sieve, and the D50 after granulation is 550-700μm; S4, total mixing: put the granulated granules into the total mixer, add the flow aid and lubricant to mix; S5, tableting: add the mixed phloroglucinol immediate-release intermediate into the 1# hopper of the double-layer tablet press, add the sustained-release intermediate into the 2# hopper of the double-layer tablet press, and compress the mixture into tablets; Method B comprises the following steps: S1. Mixing materials: according to the weight ratio of the raw and auxiliary materials of the sustained-release part, take phloroglucinol, filler, sustained-release agent and adhesive and mix them evenly; S2. Material preparation: Granulate with a dry granulator, and granulate the granules after granulation, and the D50 after granulation is 450-550μm; S3, total mixing: put the granulated granules into the total mixer, add the flow aid and lubricant for mixing; S4, tableting, adding the mixed phloroglucinol quick-release intermediate into the 1# hopper of the double-layer tablet press, adding the sustained-release intermediate into the 2# hopper of the double-layer tablet press, and tableting is performed.
6. The phloroglucinol dual-release preparation according to claim 1, characterized in that: The preparation method of the capsule comprises the following steps: (1) Immediate release part S1. According to the weight ratio of the raw materials and auxiliary materials of the immediate release part, phloroglucinol, filler, disintegrant, and 45%-55%wt of the binder are mixed evenly and set aside; S2. Use the remaining adhesive to add 25%-35% v / v ethanol solution to prepare a wetting solution for later use; S3, adding a binder to the mixed material in S1 to prepare a wetting liquid to prepare a soft material, and extruding, spheronizing and drying the soft material to obtain quick-release pellets; (2) Sustained-release part: according to the weight ratio of the raw materials and excipients of the sustained-release part, phloroglucinol, filler, sustained-release agent and binder are mixed evenly, and a soft material is prepared with a 25%-35% v / v ethanol solution; the soft material is extruded, spheronized and dried to obtain rapid-release pellets; (3) Filling capsules: Put the quick-release pellets and sustained-release pellets into capsules.
Citation Information
Patent Citations
Sustained-release preparation containing hydrochlorothiazide and preparation method thereof
CN101084903A
